4. Bibliografía

1. Kasper Carol. Trastornos de los Factores de Coagulación del plasma y su manejo. Federación Mundial de Hemofilia. Septiembre 1.996. N°004

2. Timothy M. Cox, John Sinclair. Hemofilia: la biología molecular en el centro de la enfermedad humana. Biología Molecular en Medicina. Editorial Panamericana, 1.998

3. Federación Mundial de Hemofilia. Temas clave en el tratamiento de la hemofilia: Productos y Atención. Febrero 1.997

4. Hemophilia Galaxy. Hemophilia Enciclopedia. Baxter. Ultima revisión, Julio 2.003

5. De Brasi Carlos, Slavutsky Irma, Larripa Irene. Genética Molecular de la Hemofilia A. Medicina. Vol 56, N° 5/1, 1.996

6. Reina Manuel. Métodos en Biología celular. Cromatografía. Material docente. Octubre 2.002

7. Briones Eduardo, de Pablos José María, Beltrán Calvo Carmen. Uso adecuado de Factor VIII en el tratamiento de la hemofilia A. Consejería de Salud. Agencia de Evaluación de Tecnologías Sanitarias de Andalucía. Conferencia de Consenso. Sevilla, Noviembre 2.000

8. Farrugia Albert. Guía para la evaluación de concentrados de factores de coagulación para el tratamiento de la hemofilia. Federación Mundial de Hemofilia. Montreal, Québec 2.003

9. Kasper Carol, Costa e Silva Meirione. Registro de factores concentrados de la coagulación. Federación Mundial de Hemofilia. Hechos y Cifreas. Cuarta Edición., N°6. Abril de 2.003

10. Quintana Sandra, Martínez-Murillo Carlos, Ambriz Raúl, Collazo Juan. Empleo de Productos de Coagulación: ¿Cuál elegir?. Revista de Hematología. Vol 2, N° 2. Año 2.001:67:69

11. Mammen Eberhard, Berntorp Erick. Modern Management of Hemophilia A to prevent Bleeding and Arthiopathy. Seminars in Thrombosis and Hemostasis. Vol 29, N°1, 2003

12. NHS Northern and Yorkshire. Regional Drug and Therapeutics Centre. Use of Recombinant Factor VIII in the Management of Haemophilia A. March, 1.997

13. European Pharmapoeia. Human Coagulation Factor VIII. Versión 4.5. European Directory Quality Medicaments. Año 2.003

14. United States Pharmacopoeia. Versión 25. Año 2.002

15. Feldschuh J, Enson Y. Prediction of the Normal Blood Volume. Relation of blood Bolume to Body Habitus. Circulation 56: 605-612, 1.977

16. Nilsson IM, Kirkwood BL, Barrowcliffe TW. In Vivo Recovery of Factor VIII: A Comparison of One-Stage and Two-Stage Assay Methods. Thrombosis and Haemostasis 42: 1.230-1.239, 1.979

17. Allain, JP, Verroust F, Soulier JP. In vitro and in vivo Characterization of Factor VIII Preparations. Vox Sang. 38: 68-80, 1.980

18. Allain JP. Principles of in vivo recovery and survival studies. Scandinavian Journal of Haematology 33 (Suppl. 41): 123-130, 1.984

19. Kjellman, H. Calculations of Factor VIII in vivo Recovery and Half-life. Scand J Haematol. Suppl 40. Vol 33: 165-174, 1.984

20. Rosen, S. Assay of Factor VIII:C with a Chromogenic Substrate. Scand J Haematol. Suppl. 40. Vol 33: 139-145, 1.984

21. Matucci M, Messori, G ans cols. Kinetic evaluation of four Factor VIII concentrates by model-independent methods. Scand J Haematol. 34: 22-28, 1.985

22. Longo G, Matucci M and cols. Pharmacokinetics of a new heat-treated concentrate of Factor VIII estimated by model-independent methods. Thrombosis Research 42; 471-476, 1.986

23. Harrison J, Bloom A, Abildgaard Ch. The pharmacokinetics of Recombinant Factor VIII. Seminars in Hematology, Vol 28. N°2, Suppl 1; 29-35, 1.991

24. Kasper C, Kim H, Gomperts E and cols. In vivo Recovery and Survival of Monoclonal-Antibody-Purified Factor VIII Concentrates. Thrombosis and Haemostasis 66 (6); 730-733, 1.991

25. Morfini M, Longo G, Messori A and cols. Pharmacokinetic Properties of Recombinant Factor VIII Compared with a Monoclonally Purified Cocentrate (Hemofil® M). Thrombosis and Haemostasis 68 (4); 433-435, 1.992

26. Martinowitz U, Schulman S, Gitel S and cols. Adjusted dose continuous infusion of factor VIII in patients with haemophilia A. British Lournal of Haematology, 82: 729-734, 1.992

27. Björkman S, Carlsson M, Berntorp E, Stenberg P. Pharmacokinetics of Factor VIII in Humans. Clin. Pharmacokinet. 22 (5): 385-395, 1.992

28. Barrowcliffe T. Recommendations for the Assay of High-Purity Factor VIII Concentrates. Thrombosis and Haemostasis. 70 (5): 876-877, 1.993

29. Schulman S, Gitel S, Martinowitz U. Stability of Factor VIII Concentrates After Reconstitution. American Journal of Hematology 45: 217-223, 1.994

30. Schulman S, Varon D, Keller N and cols. Monoclonal Purified FVIII Continuous Infusion: Stability Microbiological Safety and Clinical Experience. Thrombosis and Haemostasis 72 (3): 403-7, 1.994

31. Fijnvandraat K, Marjolein P, Ten Cate W. Inter-individual variation in half-life of infused recombinant factor VIII is related to pre-infusion von Willedrand factor antigens levels. British Journal of Haematology 91: 474-476, 7.995

32. Giangrande Paul. Recombinant blood products for the treatment with haemophilia. Personal Comunication. 1995

33. Menache D, Aronson D, Darr F. Pharmacokinetics of von Willebrand factor and factor VIIIC in patients with severe von Willebrand disease (type 3 vWD): estimation of the factor VIIIC synthesis. British Journal of Haematology, 94:740-745, 1.996

34. Dedik D, Batorova A, Sakalova A, Hedera J. Pharmacokinetics of factor VIII in hemophilia patients assessed by frequency response method. Methods Find Exp Clin Pharmacol, April; 20(3): 217-26, 1.998

35. Lee CA, Owens D, Bray G and cols. Pharmacokinetics of recombinant factor VIII (recombinate) using one-stage clotting and chromogenic factor VIII assay. Thrombosis Haemostasis, Dec; 82(6):1644-7, 1.999

36. Saez A, Bosh N, Boadas A, Argüello A and cols. Pharmacokinetics and acute tolerance of double virus inactivated plasma derived factor VIII concentrate. Haemophilia 5: 260-265, 1.999

37. Shirahata A, Fukutake K, Takamatsu J and cols. Pharmacokinetics, prophylactic effects and safety of a new recombinant FVIII formulated with sucrose (BAY 14-2222) in Japanese patients with hemophilia A. Int J Hematol Jul; 72(1):101-7, 2.000

38. Abshire TC, Brackmann H, Scharrer I and cols. Sucrosa Formulated Recombinant Human Antihemophilic Factor VIII is Safe Efficacious Treatment of Hemophilia A in Home Therapy. Thromb Haemost 83:811-6, 2.000

39. Björkman S, Berntorp E. Pharmacokinetics of Coagulation Factors. Clinical Relevance for Patients with Haemophilia. Clin Pharmacokinet, 40 (1):815-832, 2.001

40. Morfini S, Lee M, Schulman J. Scientific and Standardization Committee Communication. The Design and Analysis of Pharmacokinetic Studies of Coagulation Factors. Scientific and Standardization Committee of the International Society for Thrombosis and Hemostasis. Posted on ISTH Wbwsite 21 March, 2.001

41. Morfini M. Comparative pharmacokinetic studies in haemophilia. Haemophilia Mar; 8 (Suppl) 2:30-3, 2.002

42. Lee Ch. The Use of Recombinant Factor VIII Products in Previously Treated Patients with Hemophilia A: Pharmacokinetics, Efficacy, Safety and Inhibitor Development. Seminars in Thrombosis and Hemostasis. Vol 28, Number 3, 2.002

43. Mikaelsson M, Oswaldsson U, Assaying the Circulating Factor VIII Activity in Hemophilia Patients Treated with Recombinant Factor VIII Products. Seminars in Thrombosis and Hemostasis. Vol 28, Number 3, 2.002

44. Haciéndole frente al desafío. Monografía sobre el producto Koate-DVI. Bayer. 2.002

45. Octanate. Monografía. Laboratorio Octapharma. Ultima revisión Septiembre 2.002

46. Recombiant Factor VIII. Monografía del producto. Bayer. 2.002

47. Hemofil M. Monografía del producto. Baxter Healthcare Corporation. Hyland Division. 2.002

48. Berntorp E, Björkman S. The pharmacokinetics of clotting factor therapy. Haemophilia 9, 353-359. 2.003

49. Vossebeld P, Tissing M, Van der Berg H and cols. In vivo recovery and safety of human factor VIII product AAFACT® in patients with haemophilia A. Haemophilia 9: 157-163, 2.003

50. Lusher JM, Lee CA, Kessler CM and cols. The safety and efficacy of B-doamin deleted recombinat factor VIII concentrate in patients with severe haemophilia A. Haemophilia 9: 38-49, 2.003

51. Dimichele D, Miller FG, Fins JJ. Gene therapy ethics and haemophilia : an inevitable therapeutic future ?. Haemophilia 9: 145-152, 2.003

52. United Kingdom Haemophilia Centre Doctors' Organisation. Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. Haemophilia 9: 1-23, 2.003

53. Stonebraker JS, Amand RE, Nagle AJ. A country-by-country comparison of the concentrate consumption and economic capacity for the global haemophilia community. Haemophilia 9: 245-250, 2.003

54. Morfini M. Pharmacokinetics of factor VIII and factor IX. Haemophilia 9 Suppl 1:94-100, May 2.003